Century TherapeuticsIPSC
NASDAQBiotech
No cached AI snapshot yet for IPSC.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
78 employees179.72M shares outstandinglisted 2021-06-18
Next earnings ~May 5, 2026
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Latest News
Showing market-wide stock news
Century Therapeutics CTO Gregory Russotti sells $4,992 in stock
Century Therapeutics SVP Douglas Carr sells $3,199 in shares
Five Reasons Treasury Bond Yields Will Plummet In The Next Year
Fed: A rate increase backed by hawkish dots and rhetoric would support short-term yields
Euro zone yields linger at multi-year peaks as traders brace for Fed rate decision
US Dollar: Warsh guidance keeps Greenback supported – ING
Related Stocksin Biotech
Ready to see the live AI view on IPSC?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing IPSC side-by-side with live signals.